With nearly three-quarters of the year now in the books, I can't help but point out that the majority of reports up until now have been better than expected. With so many companies reporting during the weeks that comprise earnings season, it's easy for some earnings reports to fall through the cracks.
Each week this year, I've taken a look at three companies that could be worth further research after either beating or missing their profit expectations. Today, we'll take a gander at three more companies that reported earnings last week. They may have slid under your radar, but they deserve a look.
Bed Bath & Beyond
Source: Yahoo! Finance.
Happy 21st, Rite Aid shareholders! Normally turning 21 is a reason to celebrate, but this marked the 21st consecutive quarter that Rite Aid has lost money -- an ominous streak for sure. Optimists continue to point to Rite Aid's loyalty rewards program, the benefit from generic drugs helping pharmacy sales, and the customers gained from the struggles of Walgreen
For shareholders, it looks like it's going to be more of the same going forward. Although general merchandise same-store sales figures rose 1.4%, pharmacy same-store sales (which are of much higher importance) dropped 0.7%. Rite Aid did fill 4% more prescriptions than it did in the year-ago quarter, but total revenue still fell by $40 million. Furthermore, Rite Aid reduced its full-year sales forecast while tightening its EPS loss view to a range below Wall Street's current consensus. All the while, Rite Aid's CEO and executive board are getting richer. At some point you have to say enough is enough, and I'm well past that point with Rite Aid.
Bed Bath & Beyond
Finally, a little bit of reality in the home furnishings sector! I'm aware that housing data has been ticking higher and home remodel destinations are doing well, but we're talking about Bed Bath & Beyond here, not do-it-yourself warehouse Home Depot.
For the quarter, Bed Bath & Beyond reported a 5.4% increase in net income and a 12.1% rise in overall sales for the second quarter, but issued a gloomy forecast for the remainder of the year (in addition to missing Wall Street's second-quarter EPS forecast). The company has had to boost its use of coupons in order to drive customer traffic, which is never good for margins in the near-term. Competition among rivals remains fierce and online prices remain a threat to undercut Bed Bath & Beyond's in-store product line. This week's report did little to change my opinion of the company and I remain decidedly bearish on its outlook and growth prospects.
Well, isn't this an interesting switch? Previously, U.S.-based solar panel maker First Solar
In terms of misses, this one ranks right up there as epic. LDK is forecasting third-quarter revenue of $220 million to $260 million, which isn't even in the same solar system as Wall Street's estimate of $453.6 million. The company also slashed its full-year sales outlook by roughly 25% on the top and bottom end while shedding close to 3,900 workers during the second quarter. LDK's cash situation is just as dire, with just $296.2 million remaining in cash and cash equivalents. It looks like Foolish solar guru Travis Hoium's call on LDK's potential demise last October may turn out to be quite prescient.
Sometimes an earnings beat or miss isn't as cut-and-dried as it appears. I've given my two cents on what's next for each of these companies -- now it's your turn to sound off. Share your thoughts in the comments section below, and consider adding these stocks to your free and personalized Watchlist.
Is a shakeout in the solar industry going to be good or bad for First Solar over the long run? Find out the answer to this question and much more by getting your copy of our latest premium research report on First Solar. Packed with in-depth and unbiased analysis, this report highlights the opportunities and threats facing First Solar over the long run, and comes with a year of regular updates. Claim your investing edge and click here to get this report.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool owns shares of Express Scripts. Motley Fool newsletter services have recommended buying shares of Express Scripts, Home Depot, and Bed Bath & Beyond. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that always exceeds expectations.
More from The Motley Fool
Why Bed Bath & Beyond Stock Plunged 46% in 2017
Profits slumped as the retailer cut prices in response to weak demand.
Bed Bath & Beyond's New Store Strategy Carries Risk
The home furnishings specialist wants its stores to be a springboard for a turnaround.
Bed Bath & Beyond (BBBY) Q3 2017 Earnings Conference Call Transcript
BBBY earnings call for the period ending November 25, 2017.